Investigational Drug Development

Looking Forward

Fujifilm is conducting research to study the potential of new drugs to address unmet medical needs, focusing on cancer, infectious diseases and central nervous system diseases.

Fujifilm currently has clinical trials in the United States for influenza, cancer, Alzheimer’s disease and COVID-19. These clinical trials are underway in collaboration with various institutions throughout the country.

In 2016, Fujifilm provided the anti-influenza drug favipiravir (T-705) to the Guinean Government, as one of the supplies procured by the Japanese government’s emergency grant aid to counter the outbreak of Ebola Virus disease.

*Avigan Tablet has not been approved by the FDA for use in the USA


Investigational drug pipeline

Infectious diseases

Code Mode of Action Indication Region Stage Clinical Trial Information
T-705 RNA polymerase inhibitor Influenza Japan Approved
U.S.A. Phase 3
Severe fever with thrombocytopenia syndrome Japan Phase 3
Coronavirus disease 2019 (COVID-19) Japan IND filing
U.S.A. Phase 2
T-3811 Bacterial DNA gyrase inhibitor,
topoisomerase V inhibitor
Respiratory and urinary tract infection China IND filing  
T-4288 Bacterial protein synthesis inhibitor Otorhinolaryngologic infections Japan IND filing  
Respiratory tract infections Japan NDA filing


Code Mode of Action Indication Region Stage Clinical Trial Information
FF-10502-01 DNA polymerase inhibitor Advanced solid tumors U.S.A. Phase 2
FF-21101 Anti P-cadherin antibody,
90Y conjugate
Advanced solid tumors Japan Phase 1
U.S.A.1 Phase 2
FF-1311 PSMA-targeted imaging agent, 99mTc labeled Prostate cancer Japan Phase 2  
F-1515 Somatostatin receptor targeted agent, 177Lu labeled Neuroendocrine tumors Japan IND filing  
F-1614 Adrenergic neuron-blocking agent,
131I labeled
Pheochromocytoma and paraganglioma Japan IND filing  
FF-10101-01 FLT3 inhibitor Acute myeloid leukemia U.S.A. Phase 1
FF-10832 Liposomal gemcitabine
(DNA replication polymerase inhibitor)
Advanced solid tumors U.S.A. Phase 2
FF-10850 Liposomal topotecan
(topoisomerase I inhibitor)
Advanced solid tumors U.S.A. Phase 1

1 Phase 1 expansion study


Code Mode of Action Indication Region Stage Clinical Trial Information
T-817MA Neuroprotectant, microglial modulator, neuroplasticity facilitator Alzheimer’s disease Japan Phase 2


Code Mode of Action Indication Region Stage Clinical Trial Information
FF-10501-01 IMPDH inhibitor Myelodysplastic syndromes Japan Phase 1
The drug candidates created or tested by direct or indirect affiliates of FUJIFILM Holdings Corporation that are referred to on this page are still at development stage and not yet approved for commercialization. A future use and commercialization will be subject to the prior granting of a marketing authorization in the given territory and compliance with applicable laws.

Expanded access/Compassionate use

Currently, FUJIFILM Pharmaceuticals U.S.A., Inc. is not accepting expanded access/compassionate use requests.

Partnership Strategy

We are seeking the following partners:

  • Companies interested in clinical development and commercialization of Fujifilm’s pipeline drugs.
  • Companies willing to provide immune checkpoint inhibitors for, and/or co-sponsor clinical development of, combination therapies with Fujifilm liposomal drugs (FF-10832 and FF-10850).